[Future drug targets for Parkinson's disease]. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Bulletin de l'Académie Nationale de Médecine Year : 2012

[Future drug targets for Parkinson's disease].


Parkinson's disease is characterized by a triad of cardinal motor symptoms (bradykinesia, rigidity and tremor) resulting from the loss of dopaminergic neurons in the substantia nigra. This synucleinopathy is classified in the larger group of Lewy body disorders. Currently, these symptoms are relatively well alleviated by drugs that restore dopaminergic neurotransmission, andlor by deep brain stimulation. It is not yet possible to halt the underlying degeneration, or to treat symptoms due to non-dopaminergic neuron damage. This review examines the mechanisms of neuronal degeneration in Parkinson's disease, new targets for neuroprotection, and the mechanisms causing symptoms resistant to current treatments.
Fichier principal
Vignette du fichier
HIRSCH_Version_16_1_12_2_RevueBullAcadMed.pdf (213 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

inserm-00850568 , version 1 (07-08-2013)


  • HAL Id : inserm-00850568 , version 1
  • PUBMED : 23815021


Etienne C. Hirsch. [Future drug targets for Parkinson's disease].. Bulletin de l'Académie Nationale de Médecine, 2012, 196 (7), pp.1369-77; discussion 1377-9. ⟨inserm-00850568⟩
570 View
668 Download



Gmail Facebook Twitter LinkedIn More